Met Proto-oncogene Product Is Overexpressed in Tumors of p53-deficient Mice and Tumors of Li-Fraumeni Patients

Sing Rong, Michael Jeffers, James H. Resau, Eric Hudson, IIan Tsarfaty, George F. Vande Woude, Lawrence A. Donehower, Marc F. Hansen, Louise Strong, Michael Tainsky, IIan Tsarfaty

Research output: Contribution to journalArticlepeer-review

Abstract

Inappropriate expression of Met, the receptor for hepatocyte growth factor/scatter factor, has been implicated in sarcomagenesis via an autocrine mechanism. Sarcomas occur at high frequency in individuals with Li-Fraumeni syndrome as well as in p53-deficient mice. Here we show that these tumors express high levels of Met Moreover, late passage fibroblast cell lines established from p53-deficient animals overexpress Met and can be tumorigenic in athymic nude mice, suggesting that progression occurs in vitro. The tumor explants display increased hepatocyte growth factor/scatter factor expression and Met turnover, indicating that autocrine Met activation contributes to tumor progression. Thus, the loss of wild-type p53 appears to greatly enhance the opportunity for inappropriate Met expression. Loss of p53 function does not by itself cause transformation, but inappropriate Met expression may be an important factor in sarcomagenesis.

Original languageEnglish
Pages (from-to)1963-1970
Number of pages8
JournalCancer Research
Volume55
Issue number9
StatePublished - 1 May 1995

Fingerprint

Dive into the research topics of 'Met Proto-oncogene Product Is Overexpressed in Tumors of p53-deficient Mice and Tumors of Li-Fraumeni Patients'. Together they form a unique fingerprint.

Cite this